Ceftazidime-Avibactam Use in Myasthenia Gravis Patients
Ceftazidime-avibactam can be used in patients with myasthenia gravis, as there is no documented contraindication or specific neuromuscular transmission interference with this antibiotic combination, unlike certain other antimicrobial classes.
Key Safety Considerations
No Direct Contraindication
- The FDA prescribing information for ceftazidime-avibactam does not list myasthenia gravis as a contraindication or require special precautions for patients with neuromuscular disorders 1.
- Ceftazidime-avibactam is approved for complicated intra-abdominal infections, complicated urinary tract infections, and hospital-acquired/ventilator-associated bacterial pneumonia in adults and pediatric patients 1.
Antibiotics to Avoid in Myasthenia Gravis
The primary concern in myasthenia gravis patients is avoiding antibiotics that interfere with neuromuscular transmission:
- Fluoroquinolones (ciprofloxacin, levofloxacin, moxifloxacin) are well-documented to exacerbate myasthenia gravis by blocking neuromuscular transmission and should be avoided when possible 2, 3, 4.
- Fluoroquinolones caused MG exacerbation in approximately 2.4% of ciprofloxacin episodes and 1.6% of levofloxacin episodes, with some cases resulting in myasthenic crisis 4.
- Aminoglycosides (streptomycin, amikacin, kanamycin) can cause neuromuscular blockade and should be used with extreme caution, particularly in patients with myasthenia gravis 5.
Ceftazidime-Avibactam Safety Profile
- Ceftazidime-avibactam's most common adverse effects include diarrhea, nausea, and vomiting, with no specific neuromuscular adverse effects listed in the prescribing information 1.
- Central nervous system adverse events (encephalopathy, myoclonus) have been reported with ceftazidime-avibactam, particularly in patients over 65 years old with prolonged treatment courses, but these are not related to neuromuscular junction dysfunction 6.
- The safety profile is consistent with ceftazidime alone and typical of injectable cephalosporins 7.
Clinical Decision-Making Algorithm
When Ceftazidime-Avibactam is Appropriate
Use ceftazidime-avibactam for myasthenia gravis patients when:
- Treating carbapenem-resistant Enterobacterales (CRE) - particularly KPC-producing organisms where ceftazidime-avibactam 2.5 g IV every 8 hours is recommended 8.
- Treating difficult-to-treat Pseudomonas aeruginosa - ceftazidime-avibactam 2.5 g IV every 8 hours is a recommended option 8.
- When fluoroquinolones would otherwise be indicated - ceftazidime-avibactam provides an alternative that avoids neuromuscular transmission interference 2, 4.
Dosing Adjustments
- Standard dosing: 2.5 grams (ceftazidime 2 grams and avibactam 0.5 grams) IV every 8 hours over 2 hours 1.
- Renal adjustment is critical: For creatinine clearance 31-50 mL/min, reduce to 1.25 grams every 8 hours; for CrCl 16-30 mL/min, reduce to 0.94 grams every 12 hours 1.
- Monitor renal function daily in patients with changing renal status, as decreased clinical response occurs with inadequate dose adjustment 1.
Important Caveats
Infection as a Trigger
- Underlying infections themselves are the most common cause of myasthenia gravis exacerbations (88.2% of cases), independent of antibiotic choice 4.
- Active treatment of infections is essential, as untreated infections pose greater risk than most antibiotic choices 9, 2.
High-Risk Patient Factors
Monitor closely in myasthenia gravis patients with:
- Recent MG-related hospitalization or ED visit in the preceding 6 months 4
- Female sex and diabetes, which are associated with higher exacerbation risk 4
- Age over 65 years, where very late-onset MG may present with respiratory insufficiency 10
Alternative Considerations
If ceftazidime-avibactam is not suitable due to resistance patterns:
- Meropenem-vaborbactam 4 g IV every 8 hours for CRE infections 8
- Imipenem-cilastatin-relebactam 1.25 g IV every 6 hours for CRE infections 8
- Tigecycline may be used for complicated intra-abdominal infections, though not as monotherapy for pneumonia 8, 2